 | Up a level |
Barlesi, F., Wolf, J., Ahn, M-J., Doebele, R. C., Paz-Ares, L., Rolfo, C., Siena, S., Seto, T., Ohe, Y., Ou, S. H. I., Krebs, M. G., Kapre, A., Piault-Louis, E., McCallum, S., Osborne, S., Aziez, A. and Drilon, A. (2020). Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. Ann. Oncol., 31. S. S1391 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Doebele, R., Ahn, M., Siena, S., Drilon, A., Krebs, M., Lin, C., De Braud, F., John, T., Tan, D., Seto, T., Dziadziuszko, R., Arkenau, H., Barlesi, F., Rolfo, C., Wolf, J., Chow-Maneval, E., Multani, P., Cui, N., Riehl, T. and Cho, B. C. (2018). Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 13 (10). S. S321 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Felip, E., Minotti, V., Soo, R., Wolf, J., Solomon, B., Tan, D. S. W., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Paz-Ares, L., Rodriguez-Abreu, D., Garcia Campelo, M. R., Sprauten, M., Djentuh, L. O'Sullivan, Belli, R., Glaser, S., Zou, M., Giovannini, M. and Yang, J. C-H. (2020). MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer. Ann. Oncol., 31. S. S829 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Janne, P. A., van den Heuvel, M., Barlesi, F., Cobo, M., Mazieres, J., Crino, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., Poltoratskiy, A., Mariani, G., Ghiorghiu, D., Kilgour, E., Smith, P., Kohlmann, A., Carlile, D., Lawrence, D., Bowen, K. and Vansteenkiste, J. F. (2016). Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Paz-Ares, L., Barlesi, F., Siena, S., Ahn, M-J, Drilon, A., Conley, A., Rolfo, C., Wolf, J., Seto, T., Doebele, R., Kapre, A., Chen, D., McCallum, S., Osborne, S. and Demetri, G. (2021). Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open, 6 (3). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Schuler, M., Li, B. T., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G. K., Price, T., Borghaei, H., Kato, T., Takahashi, T., Spira, A., Ramalingam, S., Besse, B., Barlesi, F., Tran, Q., Henary, H., Ngarmchamnanrith, G., Govindan, R. and Wolf, J. (2021). Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis. Pneumologie, 75. S. S38 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790